Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aino Health ABFRA:50V 29 3-Year EBITDA Growth Rate is 57.50% as of Jun. 2026, which is 55% above its 10-year median of 37.05. GuruFocus rates FRA:50V with a GF Score™ of 29/100. The stock has 5 warning signs investors should review. Among 526 Healthcare Providers & Services companies, Aino Health AB ranks better than 93.35% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 57.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 48.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Aino Health AB was 57.50% per year. The lowest was -302.60% per year. And the median was 37.05% per year.
Aino Health AB (FRA:50V) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Aino Health AB 3-Year EBITDA Growth Rate Related Terms
FRA:50V vs VEEV, BTSG, TEM: 3-Year EBITDA Growth Rate Comparison
For the Health Information Services subindustry, Aino Health AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aino Health AB 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Aino Health AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Aino Health AB's 3-Year EBITDA Growth Rate falls into.
Aino Health AB 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 57.50% mean?
Aino Health AB (FRA:50V) has a 3-Year EBITDA Growth Rate of 57.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Aino Health AB and its competitors. This is 55% above median its historical median of 37.05. According to the industry distribution chart, Aino Health AB ranks #35 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 6.7%.
Is Aino Health AB's 3-Year EBITDA Growth Rate too high?
Aino Health AB's current 3-Year EBITDA Growth Rate of 57.50% is 55% above median its 10-year median of 37.05. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.05. Aino Health AB's value of 57.50% is 472.1% above this industry median. Based on the distribution chart, Aino Health AB ranks #35 out of 526 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Aino Health AB has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Aino Health AB's 3-Year EBITDA Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Aino Health AB ranks #35 out of 526 companies for 3-Year EBITDA Growth Rate. This places Aino Health AB in the top 7% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 10.05. Aino Health AB's value of 57.50% is 472.1% above this benchmark. While the company's 10-year median is 37.05 vs. the industry median of 10.05, Aino Health AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.05, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aino Health AB's current 3-Year EBITDA Growth Rate of 57.50% is 472.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Aino Health AB and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aino Health AB's current 3-Year EBITDA Growth Rate is 57.50%, which is 55% above median its own 10-year median of 37.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aino Health AB stock overvalued right now?
Aino Health AB (FRA:50V) has a current 3-Year EBITDA Growth Rate of 57.50%. The current 3-Year EBITDA Growth Rate is 57.50%, which is 55% above median its 10-year median of 37.05 and 472.1% above the Healthcare Providers & Services industry median of 10.05. Aino Health AB's overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Aino Health AB (FRA:50V), the current 3-Year EBITDA Growth Rate is 57.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aino Health AB provides corporate health management solutions. The company has developed a complete system of IT-based services with a focus on improving corporate health and reducing sickness absence levels in private and public organizations. Its solution consists of HealthManager, HealthDesk, and Consulting services. Company SaaS platform combines advance data analytics, research-based insights, and AI to empower leaders to unlock the full potential of their teams and to foster a healthier, more sustainable work environment.
29GF Score
Get the complete analysis for FRA:50V
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:50V has been successfully added to your 
